Medtronic plc. (MDT)
|Net Income (ttm)||3.88B|
|Ex-Dividend Date||Jun 24, 2021|
|Day's Range||129.17 - 130.83|
|52-Week Range||97.46 - 135.89|
|Price Target||145.56 (+12.2%)|
|Est. Earnings Date||Nov 23, 2021|
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX product... [Read more...]
In 2021, Medtronic's revenue was $30.12 billion, an increase of 4.16% compared to the previous year's $28.91 billion. Earnings were $3.61 billion, a decrease of -24.70%.Financial Statements
According to 27 analysts, the average rating for Medtronic stock is "Buy." The 12-month stock price forecast is 145.56, which is an increase of 12.23% from the latest price.
Medtronic's (MDT) pilot program offers an advanced and scalable method to use real-world clinical data which enable quicker and appropriate care for patients at-risk of SCA.
DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has won three additional important victories in a dispute over its intellectu...
Medtronic Collaboration with Mpirik to Address Disparities in Care Associated with Sudden Cardiac Arrest
DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced a pilot program with Mpirik to address disparities in care associated with the ...
Medtronic's (MDT) Emprint Ablation Catheter Kit received Breakthrough Device Designation status from the FDA in April 2021 and is currently in development.
DUBLIN, Sept. 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the following upcoming investor conferences: 202...
Medtronic Announces NAVABLATE Study Results Released in Late-Breaking Podium Presentation at European Respiratory Soc...
Results Demonstrate Feasibility of Bronchoscopic Microwave Ablation for Certain Patients with Malignant Lung Nodules DUBLIN, Sept. 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in ...
The healthcare giant posted strong growth. But there's more to the story.
Covid-19 showed us how rapid advances in medicine and technology could create significant growth opportunities for healthcare stocks. The post 7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In ...
Medtronic met analysts' consensus revenue estimate and exceeded earnings forecasts in the first quarter of its fiscal 2022.
BetterInvesting™ Magazine Selects Medtronic as "Growth" Stock and D.R. Horton as "Undervalued" For November 2021 Issue
TROY, Mich., Sept. 1, 2021 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Medtronic PLC (NYSE: MDT) as its "Stock to Study" and D.R.
A look at stock market news.
Medtronic's (MDT) Micra TPS new study data supports the relationship of a lower risk of complications with leadless pacing.
Medtronic Plc (NYSE: MDT) touted data demonstrating reductions in reinterventions and complications with its Micra pacemaker. Medtronic's Micra Coverage with Evidence Development (CED) study showed that...
Real-World Data Demonstrate Significant Reduction in Complications and Reinterventions with Medtronic Micra Leadless ...
Results Presented at ESC 2021 Show Micra TPS Compares Favorably to Traditional Pacemakers DUBLIN, Aug. 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today a...
Medtronic recently reported its fiscal Q1 2022 results, which were better than our estimates. The company reported revenues of $8.0 billion, slightly above ours and the consensus estimate of $7.9 billion.
Wednesday Afternoon Analyst Upgrades and Downgrades: Applied Materials, Best Buy, Intuit, Medtronic, Toll Brothers an...
The markets were higher across the board near midday, after a strong two-day rally opened the trading week.
Medtronic's (MDT) Evolut FX TAVR system offers hemodynamic and durability benefits of the Evolut platform with new product and procedure enhancements.
Medtronic "beat earnings" in Q1 -- and plans to keep on doing that all year long.
The FDA has approved Medtronic plc's (NYSE: MDT) Evolut FX TAVR system, a self-expanding transcatheter aortic valve replacement (TAVR) system. The Evolut FX system incorporates the same supra-annular v...
The Delta variant will be ‘short lived,' Medtronic CEO says
Karen Parkhill, Medtronic CFO, joins Yahoo Finance Live to discuss the company's strong first-quarter financial results and break down how the company continues to advance their cardiac monitoring and A...
Medtronic CEO on earnings, revenue beat and raised outlook
Medtronic chairman and CEO Geoffrey Martha joins CNBC's "Squawk on the Street" to discuss earnings and outlook.
Medtronic's (MDT) fiscal first-quarter results reflect a strong recovery from the impact of the COVID-19 pandemic on elective procedures that the company experienced in 2020.